Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/127279
Type: Thesis
Title: The effect of menstrual cycling on genomic predictive biomarkers in premenopausal breast cancer
Author: Bernhardt, Sarah Margaret
Issue Date: 2020
School/Discipline: Adelaide Medical School
Abstract: Emerging in the clinic are new assays that use gene expression profiling to predict breast cancer response to treatment. A leading genomic assay is Oncotype DX, which quantifies a panel of 21 genes to calculate a Recurrence Score. The Oncotype DX 21-gene Recurrence Score is predictive of adjuvant chemotherapy benefit for women with early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer and is recommended in clinical guidelines for guiding adjuvant chemotherapy treatment decisions. However, genomic assays such as Oncotype DX were largely developed in postmenopausal women and it remains unclear whether they are suitable for use in premenopausal women, where fluctuations in estrogen and progesterone during the menstrual cycle could affect genomic biomarker expression. The studies described in this thesis aimed to determine how menstrual cycling affects the Oncotype DX 21-gene signature using paired breast cancer samples and mouse models of breast cancer. To investigate how Oncotype DX Recurrence Scores fluctuate in HR-positive breast cancer, paired formalin-fixed paraffin-embedded invasive breast cancer samples were collected approximately 2 weeks apart from women <50 years old, and compared to women >50 years old and women with HR-negative disease. The Oncotype DX 21-gene signature was assessed through quantitative RT-PCR and 21-gene Recurrence Scores were calculated using the Oncotype DX Recurrence Score algorithm. Increased discordance in Recurrence Scores was observed between paired breast cancer samples collected from younger women (3.2±2.5; mean±stdev) compared to older women (2.0±1.7; p=0.04) and women with HR-negative disease (2.3±1.0; p=0.02). Linear regression analysis revealed that for every one-year decrease in age, discordance in Recurrence Scores increased by 0.07 units (p=0.0035). In young women, discordances were driven by variable expression of Proliferation- and HER2-group genes. To determine whether the ovarian cycle contributes to the increased variability in Recurrence Scores observed in younger women, HR-positive mammary tumours were dissected from naturally cycling MMTV-PyMT mice at either the estrus or diestrus phase of the ovarian cycle. Tumours collected at diestrus show significant differences in expression of 6 Oncotype DX signature genes (Ki67, Ccnb1, Esr1, Erbb2, Grb7, Bag1; p≤0.05) and a significant increase in Recurrence Score (21.8±2.4; mean±SEM) compared to tumours dissected at estrus (15.5±1.9; p=0.03). Clustering analysis revealed a subgroup of tumours collected at diestrus characterised by increased expression of Proliferation- (p<0.001) and Invasion-group (p=0.01) genes, and increased Recurrence Score (p=0.01). These tumours also exhibited higher expression of Estrogen-group genes (p=0.005) suggesting increased sensitivity to hormonal fluctuations during the ovarian cycle.
Advisor: Ingman, Wendy V
Price, Timothy J
Townsend, Amanda R
Dissertation Note: Thesis (Ph.D.) -- University of Adelaide, Adelaide Medical School, 2020
Provenance: This electronic version is made publicly available by the University of Adelaide in accordance with its open access policy for student theses. Copyright in this thesis remains with the author. This thesis may incorporate third party material which has been used by the author pursuant to Fair Dealing exceptions. If you are the owner of any included third party copyright material you wish to be removed from this electronic version, please complete the take down form located at: http://www.adelaide.edu.au/legals
Appears in Collections:Research Theses

Files in This Item:
File Description SizeFormat 
Bernhardt2020_PhD.pdf4.69 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.